VEGF as a Key Mediator of Angiogenesis in Cancer

By Peter Carmeliet. Oncology, 2005

1,721 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/d1530e5584052028844cd9e994531e73f3c26774

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Oncology

Citations in the corpus

To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010, methodology): “The main targets of the tumoral endothelium include: (i) The vascular endothelial growth factors (VEGF) and their receptors, VEGFR-1 and VEGFR-2, mediate vital functions in tumor angiogenesis and neovascularization [54].”
Tumor microenvironment: The role of the tumor stroma in cancer (2007, background): “Additional immune cell populations have a less well-documented role in carcinogenesis, and are not consistent residents of the stroma with their presence restricted to specific types of tumors.”
Tumor self-seeding by circulating cancer cells (2009, background): “Aggressive cancer cells may promote tumor growth through the release of paracrine signals that enhance tumor angiogenesis and the recruitment of a supportive stroma (Carmeliet, 2005; Coussens and Werb, 2002; Joyce and Pollard, 2009; Tisty and Coussens, 2006).”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “In contrast, the second approach involves the targeting of VEGF, which will inhibit ligand-binding to the VEGFR-2 receptor (Shadidi and Sioud, 2003; Carmeliet, 2005; Byrne et al., 2008).”
VEGF as a Therapeutic Target in Cancer (2005, background): “The role of VEGF as a key mediator of angiogenesis is discussed earlier in this issue [”
Hallmarks of cancer: the next generation. (2011, neutral): “Thus, VEGF gene expression can by upregulated both by hypoxia and by oncogene signaling (Fer-rara, 2009; Mac Gabhann and Popel, 2008; Carmeliet, 2005).”
Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease (2012, background): “Side effects due to high doses of certain cytokine/growth factors, which may be required due to challenges in protein delivery, can lead to the formation of aberrant and leaky vessels (Carmeliet, 2005), hypotension (Henry et al., 2001), and tumor angiogenesis (Epstein et al., 2001).”
Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “Moreover, VEGF-A is the most important regulator of angiogenesis that plays an irreplaceable role in tumor growth, proliferation, invasion, metastasis, angiogenesis, and drug resistance.(87,88) In specific body parts, such as the heart, VEGF-B promotes neuronal survival and cardiovascular growth thr”